Media coverage about Accuray (NASDAQ:ARAY) has been trending somewhat positive this week, Accern Sentiment reports. The research group ranks the sentiment of news coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Accuray earned a coverage optimism score of 0.19 on Accern’s scale. Accern also assigned news stories about the medical equipment provider an impact score of 45.6926359723532 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
Here are some of the news stories that may have effected Accern’s rankings:
- Weekly return of Healthcare: Accuray Incorporated (ARAY) performed -4.49% negative in last week - Street Observer (press release) (streetobserver.com)
- Accuray Enhances Capital Structure Through Convertible Debt Transactions - PR Newswire (press release) (prnewswire.com)
- Accuray Incorporated (NASDAQ:ARAY) Experiences Light Trading Volume - Highlight Press (highlightpress.com)
- Trading Spotlight on Shares of Accuray Incorporated (ARAY) - Wall Street Review (thewallstreetreview.com)
ARAY has been the subject of a number of recent research reports. Jefferies Group LLC reiterated a “buy” rating and issued a $7.00 target price on shares of Accuray in a report on Friday, June 30th. Zacks Investment Research upgraded shares of Accuray from a “hold” rating to a “buy” rating and set a $5.25 target price for the company in a report on Tuesday, April 4th. BTIG Research reiterated a “hold” rating on shares of Accuray in a report on Sunday, April 30th. Finally, BidaskClub downgraded shares of Accuray from a “hold” rating to a “sell” rating in a report on Thursday. Two analysts have rated the stock with a sell rating, three have assigned a hold rating and three have given a buy rating to the company. The company presently has a consensus rating of “Hold” and an average price target of $7.04.
Shares of Accuray (ARAY) traded down 3.41% during midday trading on Friday, hitting $4.25. The stock had a trading volume of 817,895 shares. The stock’s market cap is $352.75 million. Accuray has a one year low of $3.85 and a one year high of $6.39. The firm has a 50 day moving average price of $4.50 and a 200 day moving average price of $4.76.
Accuray (NASDAQ:ARAY) last issued its earnings results on Thursday, April 27th. The medical equipment provider reported ($0.06) earnings per share for the quarter, missing the consensus estimate of $0.01 by $0.07. Accuray had a negative return on equity of 61.49% and a negative net margin of 8.61%. The business had revenue of $97.31 million for the quarter, compared to analyst estimates of $110.23 million. During the same period last year, the business posted $0.01 EPS. Accuray’s revenue was down 7.6% on a year-over-year basis. On average, equities analysts forecast that Accuray will post ($0.30) earnings per share for the current fiscal year.
About Accuray
Accuray Incorporated is a radiation oncology company. The Company develops, manufactures and markets medical devices used in radiation therapy for the treatment of cancer patients. Its products include the CyberKnife Systems, the TomoTherapy Systems, and the Radixact Delivery Treatment Platform. Its technologies, the CyberKnife and TomoTherapy Systems, are designed to deliver treatments, including stereotactic radiosurgery (SRS), stereotactic body radiation therapy (SBRT), intensity modulated radiation therapy (IMRT), image guided radiation therapy (IGRT) and adaptive radiation therapy.
Receive News & Ratings for Accuray Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accuray Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.
